Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: A UK cohort study

Clinical Infectious Diseases

Volumn 53, Issue 2, 2011, Pages 107-113

  Chalmers, James D ^a,b   Taylor, Joanne K ^a   Singanayagam, Aran ^b   Fleming, Gillian B ^a   Akram, Ahsan R ^b   Mandal, Pallavi ^b   Choudhury, Gourab ^b   Hill, Adam T ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CEFTRIAXONE; CLARITHROMYCIN; GENTAMICIN; LINEZOLID; MACROLIDE; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CEREBROVASCULAR DISEASE; CHLAMYDOPHILA PNEUMONIAE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; ENTEROBACTERIACEAE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HAEMOPHILUS INFLUENZAE; HEALTH CARE; HEALTH CARE ASSOCIATED PNEUMONIA; HOSPITAL PATIENT; HUMAN; KIDNEY FAILURE; LEGIONELLA PNEUMOPHILA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; MYCOPLASMA PNEUMONIAE; NONHUMAN; OBSERVATIONAL STUDY; PNEUMONIA SEVERITY INDEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIA; COHORT STUDIES; CROSS INFECTION; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; RISK FACTORS; TREATMENT OUTCOME;

EID: 79959711666     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir274     Document Type: Article

References (30)

1. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update .2009. Thorax 2009; 64(Suppl 3):iii1-55.
2. American Thoracic Society and the Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
3. Trotter CL, Stuart JM, George R, Miller E. Increasing hospital admissions for pneumonia, England. Emerg Infect Dis 2008; 14:727-33. (Pubitemid 351838635)
4. Polverino E, Torres A. Current perspective of the HCAP problem: is it CAP or is it HAP? Semin Respir Crit Care Med 2009; 30:239-48.
5. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128:3854-62. (Pubitemid 43062645)
6. Micek ST, Kollef KE, Reichley RM, Roubinian N, KollefMH. Health careassociated pneumonia and community-acquired pneumonia: a singlecenter experience. Antimicrob Agents Chemother 2007; 51:3568-73. (Pubitemid 47519345)
7. Zilberberg MD, Shorr AF, Micek ST, Mody SH, Kollef MH. Antimicrobial therapy escalation and hospital mortality among patients with health-care-associated pneumonia: a single-center experience. Chest 2008; 134:963-8.
8. Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health careassociated pneumonia. Arch Intern Med 2008; 168:2205-10.
9. Carratalà J, Mykietiuk A, Fernández-Sabé N, et al. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med 2007; 167:1393-9. (Pubitemid 47052438)
10. Venditti M, Falcone M, Corrao S, Licata G, Serra P. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med 2009; 150:19-26.
11. Ewig S, Welte T, Chastre J, Torres A. Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis 2010; 10:279-87.
12. Polverino E, Dambrava P, Cilloniz C, et al. Nursing home-acquired pneumonia: a 10 year single-centre experience. Thorax 2010; 65:354-9.
13. Brito V, Niederman MS. Healthcare-associated pneumonia is a heterogenous disease and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. Curr Opin Infect Dis 2009; 22:316-25.
14. Nguyen-Van-Tam JS, Openshaw PJ, Hashim A, et al. Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). Thorax 2010; 65:645-51.
15. Chalmers JD, Singanayagam A, Murray MP, Hill AT. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 2008; 121:1002-7.
16. Chalmers JD, Singanayagam A, Murray MP, et al. Risk factors for complicated parapneumonic effusion and empyema on presentation to hospital with community-acquired pneumonia. Thorax 2009; 64:592-7.
17. Chalmers JD, Singanayagam A, Akram AR, et al. Severity assessment tools for predicting mortality in hospitalised patients with communityacquired pneumonia: systematic review and meta-analysis. Thorax 2010; 65:878-83.
18. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-55. (Pubitemid 13149996)
19. Majumdar R, Eurich DT, Gamble JM, et al. Oxygen saturations less than 92% are associated with major adverse events in outpatients with pneumonia: a population based cohort study. Clin Infect Dis 2011; 52:325-31.
20. Akram AR, Singanayagam A, Choudhury G, et al. Incidence and prognostic implications of acute kidney injury on admission in patients with community-acquired pneumonia. Chest 2010; 138:825-32.
21. Chalmers JD, Al-Khairalla M, Short PM, et al. Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic. J Antimicrob Chemother 2010; 65:608-18.
22. Lim WS, Macfarlane JT. A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia. Eur Respir J 2001; 18:362-8. (Pubitemid 32776414)
23. Howard LS, Sillis M, Pasteur MC, et al. Microbiological profile of community acquired pneumonia in adults over the last 20 years. J Infect 2005; 50:107-13.
24. Torres A, Dorca J, Zalacain R, et al. Community-acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicenter study. Am J Respir Crit Care Med 1996; 154:1456-61. (Pubitemid 26391197)
25. Mier L, Dreyfuss D, Darchy B, et al. Is penicillin G an adequate initial treatment for aspiration pneumonia? A prospective evaluation using a protected specimen brush and quantitative cultures. Intensive Care Med 1993; 19:279-84. (Pubitemid 23266000)
26. Hirani NA, MacFarlane JT. Impact of management guidelines on the outcome of severe community-acquired pneumonia. Thorax 1997; 52:17-21. (Pubitemid 27047219)
27. Pifarre R, Falguera M, Vicente-de-Vera C, Nogues A. Characteristics of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Respir Med 2007; 101:2139-44. (Pubitemid 47324242)
28. Von Baum H,Welte T, Marre R, Suttorp N, Ewig S. Community acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors. Eur Respir J 2010; 35:598-605.
29. Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to Gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002; 162:1849-58.
30. Torres A, Menendez R. Enterobacteriaceae and Pseudomonas aeruginosa in community-acquired pneumonia: the reality after a decade of uncertainty? Eur Respir J 2010; 35:473-4.